AstraZeneca makes $10 billion offer for obesity drugmaker Rhythm, WSJ reports

The roughly 13% gap between Rhythm’s close and the reported offer price leaves room for a further move if talks are confirmed, but also reflects the risk that no deal materialises. The report is likely to lift interest in other mid-sized obesity and rare disease biotechs as potential targets, given the appetite large drugmakers are showing for the space. For AstraZeneca, a deal of this size is…